ReviewPharmaceutics2021
Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The Application of Machine Learning in the Development of Co-Amorphous Dry Powder Inhalation.AAPS PharmSciTech · 2026Article
- Peak Inspiratory Flow Capability for Simulated Dry Powder Inhaler Resistances in Asthma Patients Prescribed Pressurized Metered-Dose Inhalers with Valved Holding Chambers: The USE-DPI Study.Journal of clinical medicine · 2026Article
- From Classics to Nano-Excipients and Biopolymers: Pulmonary Drug Delivery Formulations.Pharmaceutics · 2026Review
- Advancing pulmonary therapy: the role of dry powder inhalation technology in lung disease management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Cardiovascular inhalation for targeted drug delivery in cardiac disease.Heart failure reviews · 2025Review
- Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.Pharmaceutics · 2025Review
- Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Flowrate Sensing and Measurement in Portable Smart Inhalers.Sensors (Basel, Switzerland) · 2024Review
- Particulate bioaerogels for respiratory drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.Pharmaceutics · 2024Review
- Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.Nanomedicine (London, England) · 2024Review
- Formulation of Resveratrol-Loaded Polycaprolactone Inhalable Microspheres Using Tween 80 as an Emulsifier: Factorial Design and Optimization.AAPS PharmSciTech · 2023Article
- Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury.Molecules (Basel, Switzerland) · 2023Article
- Digital Transformation in Healthcare: Technology Acceptance and Its Applications.International journal of environmental research and public health · 2023Article
- Feedback systems in multi-dose dry powder inhalers.Postepy dermatologii i alergologii · 2023Review
- Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery.Polymers · 2023Review
- Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.Pharmaceutics · 2022Review
- Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.Pharmaceutical research · 2022Review
- The evolving landscape of digital inhaler platforms and adherence support in chronic airways disease.Chronic respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decades, the term "drug delivery systems" (DDSs) has almost fully replaced previously used terms, such as "dosage forms", in an attempt to emphasize the importance of the drug carrier in ensuring the claimed safety and effectiveness of the product. However, particularly in the case of delivery devices, the term "system", which by definition implies a profound knowledge of each single part and their interactions, is not always fully justified when using the DDS term. Within this context, dry powder inhalers (DPIs), as systems to deliver drugs via inhalation to the lungs, require a deep understanding of the complex formulation-device-patient interplay. As of now and despite the progress made in particle engineering and devices design, DPIs' clinical performance is limited by variable patients' breathing patterns. To circumvent this pitfall, next-generation DPIs should ideally adapt to the different respiratory capacity of individuals across age, health conditions, and other related factors. In this context, the recent wave of digitalization in the health care and industrial sectors may drive DPI technology towards addressing a personalized device-formulation-patient liaison. In this review, evolving technologies are explored and analyzed to outline the progress made as well as the gaps to fill to align novel DPIs technologies with the systems theory approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.